Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28038421 | 0.82 | SMN1; SMN2 (0.60) | SMN1; SMN2L3MBTL1POLBALDH1A1KDM4E | |
| SCHEMBL6629811 | 0.80 | SMN1; SMN2 (0.48) | SMN1; SMN2L3MBTL1POLBALDH1A1KMT2A | |
| SCHEMBL28038719 | 0.79 | SMN1; SMN2 (0.56) | SMN1; SMN2L3MBTL1ALDH1A1KMT2AMEN1 | |
| SCHEMBL6363517 | 0.79 | GAA (0.46) | SMN1; SMN2GAAL3MBTL1POLBALDH1A1 | |
| SCHEMBL28038424 | 0.78 | SMN1; SMN2 (0.55) | SMN1; SMN2L3MBTL1ALDH1A1KMT2AMEN1 | |
| SCHEMBL28038427 | 0.78 | SMN1; SMN2 (0.55) | SMN1; SMN2L3MBTL1ALDH1A1KMT2AMEN1 | |
| SCHEMBL28038495 | 0.78 | SMN1; SMN2 (0.55) | SMN1; SMN2L3MBTL1ALDH1A1KMT2AMEN1 | |
| SCHEMBL3579717 | 0.78 | SMN1; SMN2 (0.52) | SMN1; SMN2L3MBTL1POLBALDH1A1KDM4E | |
| SCHEMBL1527735 | 0.77 | SMN1; SMN2 (0.51) | SMN1; SMN2L3MBTL1POLBALDH1A1KDM4E | |
| SCHEMBL27564695 | 0.77 | ALDH1A1 (0.36) | SMN1; SMN2GAAALDH1A1KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050143367-A1 | Process for the preparation of pyrazolo[4,3-d]pyrimidin-7-one compounds and intermediates thereof | PFIZER INC | 2005-06-30 | — | — | US | disclosed |
| US-6809200-B2 | REACTING 5-ACETYL-N-(3-(AMINOCARBONYL)-5-ETHYL-1-(1-ETHYL-3-AZETIDINYL)-1H-PYRAZOL4 -YL)-2-ETHOXYNICOTINAMIDE, IN PRESENCE OF ALCOHOL OR ALKOXY COMPOUND AND A HYDROXIDE TRAPPING AGENT OR BASE | PFIZER INC. | 2004-10-26 | — | — | US | disclosed |
| US-6770645-B2 | SEXUAL DISORDERS THERAPY; ANTIALLERGENS; RESPIRATORY SYSTEM DISORDERS | PFIZER INC. | 2004-08-03 | — | — | US | disclosed |
| US-6756373-B1 | SUCH AS 5-(2-BUTOXY-5-IODO-3-PYRIDINYL)-3-ETHYL-2-(2-METHOXY-ETHYL)-2,6-DIHYDRO-7H -PYRAZOLO(4,3-D)PYRIMIDIN-7-ONE; CYCLIC GUANOSINE 3',5'-MONOPHOSPHATE PHOSPHODIESTERASE INHIBITORS; ERECTILE DYSFUNCTION | PFIZER INC. | 2004-06-29 | — | — | US | disclosed |
| US-20030064990-A1 | Pharmaceutically active compounds | PFIZER INC. | 2003-04-03 | — | — | US | disclosed |
| CN-1378547-A | 5-(2-substituted-5-heterocyclylsulphenylpyrid-3-yl)-dihydropyrazolo [4,3-d] pyrimidin 7-ones as phosphodiesterase inhibitors | PFIZER LTD (US) | 2002-11-06 | — | — | CN | disclosed |
| EP-1222190-A1 | 5-(2-SUBSTITUTED-5-HETEROCYCLYLSULPHONYLPYRID-3-YL)-DIHYDROPYRAZOLO[4,3-D]PYRIMIDIN-7-ONES AS PHOSPHODIESTERASE INHIBITORS | Pfizer Limited (GB) | 2002-07-17 | — | — | EP | disclosed |
| US-20020038024-A1 | Process for the preparation of pyrazolo[4,3-d]pyrimidin-7-one compounds and intermediates thereof | PFIZER INC. | 2002-03-28 | — | — | US | disclosed |
| EP-1176147-A1 | Process for the preparation of pyrazolo[4,3-d]pyrimidin-7-ones and intermediates thereof | Pfizer Limited (GB) | 2002-01-30 | — | — | EP | disclosed |
| WO-2001027112-A1 | 5-(2-SUBSTITUTED-5-HETEROCYCLYLSULPHONYLPYRID-3-YL)-DIHYDROPYRAZOLO[4,3-D]PYRIMIDIN-7-ONES AS PHOSPHODIESTERASE INHIBITORS | PFIZER LIMITED (GB) | 2001-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020038024-A1 | Process for the preparation of pyrazolo[4,3-d]pyrimidin-7-one compounds and intermediates thereof | DPYD, HPRT1, SAMHD1 | SMN1; SMN2 2390/4885GAA 1066/4885L3MBTL1 4524/4885 |
| US-20050143367-A1 | Process for the preparation of pyrazolo[4,3-d]pyrimidin-7-one compounds and intermediates thereof | NOX4, VKORC1, DPYD | SMN1; SMN2 2682/4885GAA 1737/4885L3MBTL1 4771/4885 |
| US-20030064990-A1 | Pharmaceutically active compounds | PDE5A, PDE3A, PDE2A | SMN1; SMN2 2159/4885GAA 84/4885L3MBTL1 3625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.